Royalty Pharma (RPRX) Current Assets (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Current Assets data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 22.65% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (down 22.65% YoY), and the FY2025 full-year result was $1.5 billion, down 15.21% from the prior year.
• Current Assets fell to $1.4 billion in Q1 2026, from $1.5 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $3.5 billion in Q2 2022 to a low of $1.3 billion in Q4 2023.
• A 5-year average of $2.1 billion and a median of $1.8 billion in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets plunged 50.13% in 2023 and surged 41.43% in 2024, its largest moves.
• Tracing RPRX's Current Assets over 5 years: stood at $2.6 billion in 2022, then sank by 50.13% to $1.3 billion in 2023, then soared by 41.43% to $1.8 billion in 2024, then declined by 15.21% to $1.5 billion in 2025, then decreased by 6.69% to $1.4 billion in 2026.
• Business Quant data shows RPRX's Current Assets at $1.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.8 billion in Q3 2025.